Efficacy in Itch Relief

In a sub-analysis of the PSO-FAST study, Enstilar® provided significant and sustained itch relief1

Of 300 patients with VAS score >30, those on Enstilar® experienced a significant itch reduction
from baseline vs foam vehicle by day 3 (P=0.019), with continued improvement
for 4 weeks (P<0.001, each time point).1

Change in itch VAS scores over 4 weeks in plaque psoriasis patients with clinically relevant itch (baseline VAS score >30)1

Enstilar® (calcipotriol / betamethasone dipropionate) itch relief data

*P=0.019, †P<0.001, Enstilar® vs foam vehicle. Bars represent 95% confidence intervals (CI).
Adapted from Stein Gold L et al. EADV 2017.

Study details

PSO-FAST was a randomised, double-blind, vehicle-controlled, 4-week Phase III trial conducted in 426 patients with mild to severe plaque psoriasis. Patients included in this sub-analysis were those with a baseline itch VAS score >30, i.e., of clinical relevance,also described as itch that is at least moderate.Assessments included change in VAS scores from baseline and proportion of patients achieving a 70% reduction in itch.1,2

Enstilar® can provide itch relief through the night for better sleep

36% of Enstilar® patients experienced a 70% reduction in sleep loss due to itch at 3 days (n=87/245) vs 23% of patients using foam vehicle (n=19/83; P=0.035).2,3

This increased to 71% (n=172/243) of Enstilar® patients at week 4 vs 40% of patients using foam vehicle (n=33/83; P<0.001)2,3

Proportion of patients achieving 70% relative
reduction in itch-related sleep loss2

Enstilar® (calcipotriol / betamethasone dipropionate) sleep loss data

Patients assessed itch-related sleep loss during the night prior to each visit (baseline, days 3 and 5, and weeks 1, 2 and 4), according to a visual analogue scale (VAS, range 0–100 mm).2
Patient’s assessment of itch was a secondary outcome of the PSO-FAST trial. The primary outcome of the study was the proportion of patients at week 4 who achieved treatment success, defined as clear or almost clear (for patients with ≥moderate disease at baseline) or clear (for patients with mild disease at baseline), according to the PGA.2

Study details

PSO-FAST was a randomised, double-blind, vehicle-controlled, 4-week Phase III trial conducted in 426 patients with mild to severe plaque psoriasis. Patients included in this sub-analysis were those with a baseline itch VAS score >30, i.e., of clinical relevance,also described as itch that is at least moderate.Assessments included change in VAS scores from baseline and proportion of patients achieving a 70% reduction in itch.1,2

Enstilar® offers relief for adult plaque psoriasis patients suffering from itch

With Enstilar, patients experienced:
• Itch relief, with a statistically significant effect in 3 days vs foam vehicle.1
• Sustained relief, with continued improvement over the 4-week treatment period.1
• Relief through the night with significantly reduced sleep loss due to itch vs foam vehicle2

Case study: Relieving itch with Enstilar®

Case submitted by Dr Andreas Körber, Essen, Germany. For illustrative purposes only.

Patient's skin before treatment

Mark is suffering from psoriasis-related itch

  • Mark is a 40-year-old carpenter
  • Developed plaque psoriasis 7 years ago
  • Psoriasis is mild but with frequent, annoying itch resulting in scratching
    – Baseline PASI score of 4.4 and DLQI score of 5
  • Previously treated with local steroids as well as combination of calcipotriol and betamethasone dipropionate – These were ineffective and he struggled to adhere to treatment
Patient's skin after treatment

Enstilar® helps to offer Mark relief

  • Itchy skin resolved after one week of treatment with Enstilar®
  • 86% reduction in PASI after 3 weeks of treatment (4.4 to 0.6)
  • Impact of plaque psoriasis on everyday life resolved (DLQI reduced from 5 to 0)
  • Found Enstilar® easy to apply